Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)

Latest Ratings for AGIO
DateFirmActionFromTo Mar 2022Goldman SachsMaintainsSell Mar 2022HC Wainwright & Co.MaintainsBuy Feb 2022RBC CapitalMaintainsOutperform
View More Analyst Ratings for AGIO

View the Latest Analyst Ratings

read more Read More